Safety and tolerability of oseltamivir prophylaxis in hematopoietic stem cell transplant recipients: A retrospective case-control study

被引:57
作者
Vu, Debie
Peck, Angela J.
Nichols, W. Garrett
Varley, Cara
Englund, Janet A.
Corey, Lawrence
Boeckh, Michael
机构
[1] Fred Hutchinson Canc Res Ctr, Program Infect Dis, Seattle, WA 98109 USA
[2] Univ Washington, Seattle, WA 98195 USA
[3] Childrens Hosp & Reg Med Ctr, Seattle, WA USA
关键词
D O I
10.1086/518985
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. Oseltamivir is safe and effective in immunocompetent persons, and prophylactic use is recommended during influenza outbreaks. However, no data exist regarding the use of oseltamivir as prophylaxis among patients undergoing hematopoietic stem cell transplantation ( HSCT). Methods. In January 2002, an influenza A outbreak was identified when 4 cases occurred within 1 week at an outpatient residential facility for patients undergoing HSCT. Oseltamivir prophylaxis ( 75 mg per day) was initiated for all asymptomatic patients living in the housing facility. Retrospectively, 45 patients ( 25 of whom had undergone HSCT, and 20 of whom were pre-HSCT candidates) who received oseltamivir prophylaxis were evaluated for adverse events. These 45 patients were matched 1: 1 with control subjects who received transplants during the period 1994-2003 and did not receive prophylaxis; they were matched according to donor type, conditioning regimen, cytomegalovirus serostatus, time after HSCT, and recipient age ( +/- 5 years). The frequency of clinical and laboratory adverse events was determined by chart review and graded using National Cancer Institute Common Terminology Criteria. Results. Forty-five residents received oseltamivir for a median of 17 days ( range, 10-81 days). No new cases of influenza A occurred in the facility. Seven weeks after initiation of prophylaxis, 1 resident who had been noncompliant to prophylaxis developed an influenza B infection, followed by an additional case of influenza B that occurred in a patient who had not received prophylaxis. No deaths occurred that were attributable to prophylaxis. The proportions of clinical and laboratory adverse events meeting common terminology criteria grades 2-4 or 3-4 were not significantly different between the case patients who received oseltamivir prophylaxis and control subjects. Conclusion. Oseltamivir prophylaxis appeared to be safe and well tolerated in managing an influenza outbreak in an HSCT outpatient residence.
引用
收藏
页码:187 / 193
页数:7
相关论文
共 23 条
[1]  
[Anonymous], 2006, Common Terminology Criteria for Adverse Events v3.0 (CTCAE)
[2]   Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an Immunocompromised child [J].
Baz, Mariana ;
Abed, Yacine ;
McDonald, Jane ;
Boivin, Guy .
CLINICAL INFECTIOUS DISEASES, 2006, 43 (12) :1555-1561
[3]   Use of oseltamivir during influenza outbreaks in Ontario nursing homes, 1999-2000 [J].
Bowles, SK ;
Lee, W ;
Simor, AE ;
Vearncombe, M ;
Loeb, M ;
Tamblyn, S ;
Fearon, M ;
Li, Y ;
McGeer, A .
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2002, 50 (04) :608-616
[4]  
Chik K. W., 2004, Hong Kong Medical Journal, V10, P103
[5]   Effectiveness of neuraminidase inhibitors in treatment and prevention of influenza A and B: systematic review and meta-analyses of randomised controlled trials [J].
Cooper, NJ ;
Sutton, AJ ;
Abrams, KR ;
Wailoo, A ;
Turner, DA ;
Nicholson, KG .
BRITISH MEDICAL JOURNAL, 2003, 326 (7401) :1235-+
[6]   Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients: Focus on community respiratory virus infections [J].
Dykewicz, CA .
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2001, 7 :19S-22S
[7]  
Dykewicz CA, 2000, BIOL BLOOD MARROW TR, V6, P659
[8]  
ENGELHARD D, 1993, BONE MARROW TRANSPL, V11, P1
[9]   Management of influenza in households: A prospective, randomized comparison of oseltamivir treatment with or without postexposure prophylaxis [J].
Hayden, FG ;
Belshe, R ;
Villanueva, C ;
Lanno, R ;
Hughes, C ;
Small, I ;
Dutkowski, R ;
Ward, P ;
Carr, J .
JOURNAL OF INFECTIOUS DISEASES, 2004, 189 (03) :440-449
[10]   Use of the selective oral neuraminidase inhibitor oseltamivir to prevent influenza [J].
Hayden, FG ;
Atmar, RL ;
Schilling, M ;
Johnson, C ;
Poretz, D ;
Paar, D ;
Huson, L ;
Ward, P ;
Mills, RG .
NEW ENGLAND JOURNAL OF MEDICINE, 1999, 341 (18) :1336-1343